Le Lézard
Classified in: Health
Subjects: OFR, PVP

Aion Therapeutic Announces Closing of Non-Brokered Private Placement Offering of Units


TORONTO, Aug. 14, 2023 /CNW/ - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") is pleased to announce that further to its press released dated July 4, 2023, it has closed its previously-announced non-brokered private placement (the "Unit Offering") of 42,750,000 units ("Units") at a price of $0.01 per Unit for gross proceeds of $427,500.

Each Unit consists of one common share ("Share") and one half of one common share purchase warrant ("Warrant"). Each full Warrant is exercisable to acquire one Share ("Warrant Share") for a period of eighteen months following the closing of the Unit Offering at an exercise price of $0.10 per Warrant Share.

The Company intends to use the proceeds of the Unit Offering for general working capital purposes. All securities issued in connection with the Unit Offering are subject to a four month and one day hold as required under applicable securities laws.

This news release does not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of any of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the "1933 Act") or any state securities laws and may not be offered or sold within the United States or to, or for account or benefit of, U.S. Persons (as defined in Regulation S under the 1933 Act) except pursuant to an available exemption under the 1933 Act and compliance with, or exemption from, applicable U.S. state securities laws.

About Aion Therapeutic Inc.

Aion Therapeutic is a forward-thinking business within the health and wellness sector with a diverse portfolio of intellectual property. With a commitment to innovation and transformative solutions, the Company is poised to drive positive change to redefine the boundaries of health and wellness.

DISCLAIMER & READER ADVISORY

This release contains forward-looking information within the meaning of applicable Canadian securities legislation. Expressions such as "anticipates", "expects", "believes", "estimates", "could", "intends", "may", "plans", "predicts", "projects", "will", "would" and other similar expressions, or the negative of these terms, are generally indicative of forward-looking information. Forward looking statements in this press release include statements regarding the use of proceeds from the Unit Offering. Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those expressed or implied by such forward-looking information.

In addition, the forward- looking information contained in this release is based upon what management believes to be reasonable assumptions. Readers are cautioned not to place undue reliance on forward-looking information as it is inherently uncertain, and no assurance can be given that the expectations reflected in such information will prove to be correct. The forward-looking information in this release is made as of the date hereof and, except as required under applicable securities legislation, the Company assumes no obligation to update or revise such information to reflect new events or circumstances.

The securities of the Company have not been registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements. This release is issued for informational purposes only and does not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of any securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

The Canadian Securities Exchange (operated by CNSX Markets Inc.) has neither approved nor disapproved of the contents of this press release.

SOURCE AION THERAPEUTIC INC.


These press releases may also interest you

at 09:05
Smart Meter, the leading supplier of Cellular Remote Patient Monitoring (RPM)tm solutions, has introduced a new version of the iGlucose, its patented cellular-connected glucose meter used by over 200,000 people with diabetes since 2019. The...

at 09:00
Today, the Honourable Gary Anandasangaree, Minister of Crown-Indigenous Relations; the Honourable Patty Hajdu, Minister of Indigenous Services and Minister responsible for FedNor; the Honourable Dan Vandal, Minister of Northern Affairs; and the...

at 08:05
GE HealthCare today unveiled SIGNA MAGNUS, an FDA 510(k) pending head-only magnetic resonance (MR) scanner designed to explore advancements in neuroscience, which have been restricted by the performance limitations of conventional whole-body MR...

at 07:00
To mark National Hospice Palliative Care Week, the Quebec Coalition for Palliative Care Access (the Coalition) is proud to celebrate the positive impact of palliative care on the well-being of people with life-limiting illness. Palliative care is...

at 06:00
A native born and trained Brazilian oncologist is in the forefront of a new era in the treatment of cancer patients with cutting edge proton therapy medical technology developed in Israel by P-Cure. "It is my dream to be able to bring the P-Cure...

4 mai 2024
UroGen Pharma Ltd. , a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced results from a new analysis of the ATLAS trial, which estimates using Kaplan Meier...



News published on and distributed by: